Phase 3 Readout

CRVS: Phase 3 Topline: A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soqu

Name: Phase 3 Topline: A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soqu
Start: 2028-12-01
End: 2028-12-01

December 1, 2028. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: December 1, 2028
Company: Corvus Pharmaceuticals, Inc. (CRVS)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soqu

December 1, 2028

CRVS overview →

Company: Corvus Pharmaceuticals, Inc. (CRVS)
Indication: Lymphoma, T-Cell; Angioimmunoblastic T-cell Lymphoma; Lymphoma, T-Cell, Peripheral